Skip to main content
Premium Trial:

Request an Annual Quote

Protea Licenses Mass Spec Technology from GWU

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Protea Biosciences today announced a worldwide licensing agreement with George Washington University for mass spectrometry-based technology.

The technology, called Laser Ablation Electrospray Ionization, or LAESI, can directly identify proteins, peptides, lipids, and metabolites in biological samples, including tissue, blood, urine, and single cells, Protea said in a statement.

Developed in the laboratory of Akos Vertes, a professor of chemistry, biochemistry and molecular biology at GWU and founder and co-director of the W.M. Keck Institute for Proteomics Technology, LAESI allows an analysis to be done in less than two seconds and enables 3-dimension mapping of biomolecules through depth profiling and lateral imaging, the Morgantown, W. Va.-based company added.

Little or no sample preparation is required, Protea said.

The technology is described in a study published yesterday in PLoS One, in which Vertes and his colleagues identified virally infected human cells.

Protea and the Vertes lab will now develop instrumentation and software for the technology, it said. Terms of the agreement were not disclosed.

"We foresee a broad range of commercial applications in chemical and biological research, surgical pathology, clinical diagnostics, chemical and biological defense, forensics, agriculture, and many other fields," Steve Turner, CEO of Protea, said.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.